Ann: ACTION3 IND Approved in China, page-149

This is right DMX-200 works alongside the gold standard and not to replace it. A 10% reduction in proteinuria lowers end stage disease risk is deemed to be a clinical meaningful difference in eGFR slope. DMX Ph2 results DMX-200 produced a combined ~35% reduction in proteinuria where as current gold standard working alone achieved 18%. The combined medication is 94% (nearly double) better than when the gold standard is administered alone that is a huge improvement and no doubt ADVANZ medical experts and advisers (not randoms on the web who pretend to have more insight) were impressed enough to sign a deal.